Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer |
| gptkbp:ATCCode |
L01EM07
|
| gptkbp:brand |
gptkb:Piqray
|
| gptkbp:chemicalFormula |
C19H22F3N5O2
|
| gptkbp:combines |
gptkb:fulvestrant
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
8-9 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
alpelisib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PI3K inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
441.41 g/mol
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash hyperglycemia |
| gptkbp:target |
gptkb:PIK3CA
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:protein
|
| gptkbp:bfsLayer |
4
|